Volume 8, Supplement 6 (Dec 2017)

Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources.  This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens.